STELARA

November 2, 2016December 16, 2016

My Mixed Feelings About Switching to Stelara

Columns, Crohn's Corner - a column by Judy Walters

I’m headed to Philadelphia, where my doctor is located (I’m in New Jersey) to start my new treatment regimen of Stelara. To say I’m not looking forward to it is ... Read more

September 29, 2016

FDA Approves Stelara for Adults with Moderate-to-Severe Active Crohn’s Disease

News

Janssen Biotech recently announced that the company’s Stelara (ustekinumab) for the treatment of moderate-to-severe active Crohn’s disease in adults, has been approved by the U.S. Food and Drug Administration (FDA). Stelara is the ... Read more

September 23, 2016

European Agency Recommends Approval of Stelara to Treat Crohn’s Disease

News

The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency (EMA), has issued a positive opinion on Janssen’s Stelara (ustekinumab) for the treatment of patients with moderate-to-severe active ... Read more

May 27, 2016May 27, 2016

Crohn’s Disease Patients See Promising Results in Stelara (Ustekinumab) Phase 3 Clinical Studies, Janssen Reports

News

Janssen Research & Development drug candidate Stelara (ustekinumab) demonstrated positive results in the IM-UNITI maintenance study investigating clinical remission effects in patients with moderate to severe Crohn’s disease. The results showed that ... Read more

March 28, 2016March 28, 2016

Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results

News

Janssen Pharmaceuticals’ drug candidate Stelara (ustekinumab) demonstrated positive therapeutic effects in a recent Phase 3 clinical trial, inducing clinical response and remission in adult patients with moderate to severe Crohn’s ... Read more

December 7, 2015February 19, 2016

Janssen Submits Crohn’s Disease Drug STELARA for Approval in the United States and European Union

Crohn's Disease, News

Janssen Biotech, Inc. and Janssen-Cilag International NV, both part of the Janssen Pharmaceutical Companies of Johnson & Johnson, recently announced the submission of the company’s product STELARA® (ustekinumab), developed as ... Read more

October 22, 2015October 22, 2015

Crohn’s Disease Therapy STELARA Showed Efficacy in Phase III Trial

News

Results on a pivotal Janssen Research & Development, LLC-commissioned Phase III clinical trial, called UNITI-2, on STELARA® (ustekinumab) for moderate to severe Crohn’s disease were recently reported and provided the first evidence ... Read more